Shares of Medtronic plc (MDT.N) surged to a 52-week high following the company's impressive Q2 FY26 earnings report, which revealed a revenue increase of 6.6% to $9.0 billion and a GAAP diluted EPS rise of 8% to $1.07, surpassing analyst expectations. The stock's breakout was fueled by robust performance in the Cardiac Ablation Solutions segment, which saw a remarkable 71% revenue growth, particularly driven by the pulsed field ablation portfolio. Additionally, Medtronic raised its FY26 revenue growth guidance to approximately 5.5%, reflecting strong confidence in ongoing growth and market expansion, particularly with new product approvals enhancing its portfolio. Despite the positive outlook, some analysts express concerns over potential overvaluation in the current market.
Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 111.76 USD with a low forecast of 102.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 111.76 USD with a low forecast of 102.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 100.790
Low
102.00
Averages
111.76
High
120.00
Current: 100.790
Low
102.00
Averages
111.76
High
120.00
Bernstein
Outperform
maintain
$111 -> $112
2026-01-09
Reason
Bernstein
Price Target
$111 -> $112
AI Analysis
2026-01-09
maintain
Outperform
Reason
Bernstein raised the firm's price target on Medtronic to $112 from $111 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.
Barclays
Matt Miksic
Overweight
maintain
$111 -> $116
2026-01-08
Reason
Barclays
Matt Miksic
Price Target
$111 -> $116
2026-01-08
maintain
Overweight
Reason
Barclays analyst Matt Miksic raised the firm's price target on Medtronic to $116 from $111 and keeps an Overweight rating on the shares. The firm cites an increased target multiple for the boost to put the stock in line with the recent increase in peers.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MDT
Unlock Now
William Blair
Brandon Vazquez
Market Perform -> Outperform
upgrade
2026-01-06
Reason
William Blair
Brandon Vazquez
Price Target
2026-01-06
upgrade
Market Perform -> Outperform
Reason
William Blair analyst Brandon Vazquez upgraded Medtronic to Outperform from Market Perform without a price target as part of its 2026 outlook for the medical technology group. The company has several new and ramping launches this year, the analyst tells investors in a research note. William Blair says volumes and spending budgets "remain solid" in the medtech space with earnings estimates "finally going up." This is a good setup for medtech into 2026, contends the firm.
Truist
Richard Newitter
Hold
downgrade
$110 -> $107
2025-12-18
Reason
Truist
Richard Newitter
Price Target
$110 -> $107
2025-12-18
downgrade
Hold
Reason
Truist analyst Richard Newitter lowered the firm's price target on Medtronic to $107 from $110 and keeps a Hold rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
